Allergan plc (AGN)

NYSE - NYSE Real Time Price. Currency in USD
232.60-5.19 (-2.18%)
As of 1:37 PM EDT. Market open.
People also watch:
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Prev Close237.79
Bid231.14 x 300
Ask231.20 x 100
Day's Range229.61 - 238.13
52wk Range195.50 - 322.68
1y Target EstN/A
Market Cap92.1B
P/E Ratio (ttm)22.15
Avg Vol (3m)2,998,381
Dividend & YieldN/A (N/A)
Earnings DateN/A
Trade prices are not sourced from all markets
  • Stocks slip as drug companies fall; oil drillers climb
    Associated Press2 hours ago

    Stocks slip as drug companies fall; oil drillers climb

    NEW YORK (AP) — U.S. stocks are lower Thursday as EpiPen maker Mylan and other drug companies face scrutiny over increases in product prices. Oil prices are little changed after a big surge a day ago, but companies that drill for oil are climbing. A slide in high-dividend stocks like utilities and real estate companies is also pulling the market lower.

  • PR Newswire4 hours ago

    Allergan Issues Statement on Namenda XR Patent Litigation Following Announcement of ANDA Approvals

    DUBLIN, Sept. 29, 2016 /PRNewswire/ -- Allergan plc (AGN), today issued the following statement regarding ongoing litigation on patents related to NAMENDA XR® (memantine hydrochloride) extended release capsules following announcement of FDA final ANDA approval by Lupin. One of the licensed patent families covering Namenda XR has been held invalid by the Federal District Court for the District of Delaware.  That decision is under appeal to the U.S. Court of Appeals for the Federal Circuit. The Company will defend the validity of these patents on appeal and believes that its arguments on appeal are substantial and meritorious.

  • TheStreet.com6 hours ago

    Are Hedge Funds Technically Wrong?

    Charts show 'hedge hogs' shouldn't dump AAPL and some other big-caps.